Fir­dapse fails PhI­II for myas­the­nia gravis as Cat­a­lyst keeps look­ing for ex­pand­ed la­bel

Cat­a­lyst Ther­a­peu­tics’ quest to achieve ex­pand­ed-la­bel ap­proval for its con­tro­ver­sial Fir­dapse drug has run in­to an­oth­er stum­bling block.

In a quar­ter­ly earn­ings re­port Mon­day, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER